Skip to main content

Gefitinib

ADVERTISEMENT
Identification
Molecular formula
C22H24ClFN4O3
CAS number
184475-35-2
IUPAC name
5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine
State
State

Gefitinib is in a solid state at room temperature.

Melting point (Celsius)
196.00
Melting point (Kelvin)
469.15
Boiling point (Celsius)
690.10
Boiling point (Kelvin)
963.25
General information
Molecular weight
446.91g/mol
Molar mass
446.9150g/mol
Density
1.4215g/cm3
Appearence

Gefitinib appears as a white to slightly yellowish, crystalline powder.

Comment on solubility

Solubility of 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine

The solubility of the compound 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine (C22H24ClFN4O3) is an important characteristic that impacts its application across various fields. Generally, solubility can be influenced by several factors, including:

  • Polarity: The presence of functional groups can enhance or reduce solubility in polar or non-polar solvents.
  • Temperature: An increase in temperature can lead to higher solubility for many compounds.
  • pH Level: The solubility of amines and other functional groups might vary significantly in different pH environments.
  • Interaction with Solvent: Hydrogen bonding, van der Waals forces, and dipole-dipole interactions can dramatically affect solubility.

This specific compound is likely to possess moderate solubility in organic solvents due to its complex aromatic structure. While quinazoline moieties typically display lower water solubility, the incorporation of trimethoxyaniline substitutes can enhance solubility due to the electron-donating effects of the methoxy groups, which could interact favorably with solvents.

In conclusion, understanding solubility not only helps in predicting the behavior of the compound in various environments but also plays a critical role in its effectiveness in applications such as pharmaceuticals and agrochemicals. It is often stated that "like dissolves like," which holds true in many scenarios but must be evaluated on a case-by-case basis for compounds as intricate as this one.

Interesting facts

Interesting Facts about 5-Methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine

This intriguing compound, with a complex structure, is a member of the quinazoline family, which is renowned for its diverse biological activities. Here are some fascinating insights:

  • Pharmaceutical Potential: Quinazoline derivatives have been investigated for their potential in treating various diseases, including cancers and neurological disorders. This particular compound may exhibit significant therapeutic properties worth exploring.
  • Structural Features: The compound showcases a quinazoline core, which is often characterized by a fused bicyclic structure. This particular configuration is often pivotal in enabling the molecule to interact with biological targets.
  • Substituent Influence: The presence of the 3,4,5-trimethoxyanilino group adds to the compound's unique properties. The methoxy groups can enhance solubility and alter biological activity, making this compound a subject of interest in medicinal chemistry.
  • Research Applications: Scientists have identified similar compounds involved in enzyme inhibition and receptor binding. Therefore, this compound may pave the way for new drug development by acting as a prototype for further modifications and studies.

As researchers continue to explore and synthesize novel derivatives, understanding the intricate balance of structure and function in compounds like this one is crucial. The innovative designs in medicinal chemistry can lead to groundbreaking discoveries that benefit human health.

To quote the famous chemist Linus Pauling, “The best way to have a good idea is to have a lot of ideas.” This compound serves as a reminder of the endless possibilities that exist at the molecular level in drug design and development.

Synonyms
trimetrexate
52128-35-5
CI-898
Trimetrexato
Jb-11
Trimetrexatum [INN-Latin]
Trimetrexato [INN-Spanish]
Trimetrexatum
NSC-249008
TMQ
JB 11
NSC 249008
HSDB 6545
UPN4ITI8T4
NSC249008
Trimetrexate [USAN:INN:BAN]
5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine
TRIMETREXATE [MI]
TRIMETREXATE [INN]
CHEMBL119
TRIMETREXATE [HSDB]
TRIMETREXATE [USAN]
2,4-Diamino-5-methyl-6-((3,4,5-trimethoxyanilino)methyl)quinazoline
TRIMETREXATE [VANDF]
5-Methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-2,4-quinazolinediamine
5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)quinazoline-2,4-diamine
5-methyl-6-{[(3,4,5-trimethoxyphenyl)amino]methyl}quinazoline-2,4-diamine
2,4-Quinazolinediamine, 5-methyl-6-(((3,4,5-trimethoxyphenyl)amino)methyl)-
TRIMETREXATE [WHO-DD]
DTXSID3023714
2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline
2,4-Quinazolinediamine, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-
5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]quinazoline-2,4-diamine
Trimetrexatum (INN-Latin)
Trimetrexato (INN-Spanish)
Trimetrexate Hydrate
5-Methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-2,4-quinazolinediamine
72828-03-6
NCGC00161419-02
UNII-UPN4ITI8T4
Trimetrexate (USAN/INN)
Trimexate
Trimetrexic acid
5-Methyl-6-
251301-18-5
SCHEMBL3983
2,4-Diamino-5-methyl-6-
BIDD:GT0129
CHEBI:9737
DTXCID603714
GTPL7613
BDBM18268
P01AX07
BCP15515
EX-A10496
2,4-Quinazolinediamine,5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-
6-[((3,4,5-Trimethoxyphenyl)amino)methyl]-5-methyl-2,4-quinazolinediamine
AKOS030257627
DB01157
5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine
NCGC00161419-01
NCGC00161419-03
NCGC00161419-04
NCGC00161419-07
HY-10373
MS-25931
DB-242472
NS00068348
D06238
F85148
EN300-7481403
Q7842225
2, 5-methyl-6-[[(3,4,5-trimethoxyphenyl)amino]methyl]-
2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyphenylamino)methyl]quinazoline
615-840-9